Coloplast Statistics
Total Valuation
Coloplast has a market cap or net worth of 29.35 billion. The enterprise value is 32.79 billion.
| Market Cap | 29.35B |
| Enterprise Value | 32.79B |
Important Dates
The next estimated earnings date is Tuesday, November 5, 2024.
| Earnings Date | Nov 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
| Shares Outstanding | n/a |
| Shares Change (YoY) | +5.87% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 141.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 26.99, with an EV/FCF ratio of 152.03.
| EV / Earnings | 45.94 |
| EV / Sales | 8.56 |
| EV / EBITDA | 26.99 |
| EV / EBIT | 31.27 |
| EV / FCF | 152.03 |
Financial Position
The company has a current ratio of 0.85, with a Debt / Equity ratio of 1.48.
| Current Ratio | 0.85 |
| Quick Ratio | 0.53 |
| Debt / Equity | 1.48 |
| Debt / EBITDA | 2.94 |
| Debt / FCF | 16.34 |
| Interest Coverage | 9.13 |
Financial Efficiency
Return on equity (ROE) is 43.17% and return on invested capital (ROIC) is 12.92%.
| Return on Equity (ROE) | 43.17% |
| Return on Assets (ROA) | 10.76% |
| Return on Capital (ROIC) | 12.92% |
| Revenue Per Employee | 235,910 |
| Profits Per Employee | 44,549 |
| Employee Count | 15,692 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 2.36 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +22.49% in the last 52 weeks. The beta is 0.33, so Coloplast's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | +22.49% |
| 50-Day Moving Average | 130.08 |
| 200-Day Moving Average | 125.27 |
| Relative Strength Index (RSI) | 23.25 |
| Average Volume (20 Days) | 175 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Coloplast had revenue of 3.78 billion and earned 713.63 million in profits. Earnings per share was 3.17.
| Revenue | 3.78B |
| Gross Profit | 2.55B |
| Operating Income | 1.03B |
| Pretax Income | 907.87M |
| Net Income | 713.63M |
| EBITDA | 1.16B |
| EBIT | 1.03B |
| Earnings Per Share (EPS) | 3.17 |
Balance Sheet
The company has 127.44 million in cash and 3.52 billion in debt, giving a net cash position of -3.40 billion.
| Cash & Cash Equivalents | 127.44M |
| Total Debt | 3.52B |
| Net Cash | -3.40B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 2.37B |
| Book Value Per Share | 10.56 |
| Working Capital | -262.20M |
Cash Flow
In the last 12 months, operating cash flow was 373.41 million and capital expenditures -157.75 million, giving a free cash flow of 215.65 million.
| Operating Cash Flow | 373.41M |
| Capital Expenditures | -157.75M |
| Free Cash Flow | 215.65M |
| FCF Per Share | n/a |
Margins
Gross margin is 67.52%, with operating and profit margins of 27.38% and 18.88%.
| Gross Margin | 67.52% |
| Operating Margin | 27.38% |
| Pretax Margin | 24.02% |
| Profit Margin | 18.88% |
| EBITDA Margin | 30.73% |
| EBIT Margin | 27.38% |
| FCF Margin | 5.71% |
Dividends & Yields
Coloplast does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 95.03% |
| Buyback Yield | -5.87% |
| Shareholder Yield | -5.87% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Coloplast has an Altman Z-Score of 4.9.
| Altman Z-Score | 4.9 |
| Piotroski F-Score | n/a |